Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 89, Issue 1, Pages 97-108
Publisher
Wiley
Online
2014-01-25
DOI
10.1002/ajh.23642
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
- (2013) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
- (2013) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
- (2013) John Koreth et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
- (2012) F. Thol et al. BLOOD
- Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
- (2012) H. Makishima et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Predicting survival of patients with hypocellular myelodysplastic syndrome
- (2012) Wei-Gang Tong et al. CANCER
- Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
- (2012) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
- (2012) Julie Schanz et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
- (2012) Lambert Busque et al. NATURE GENETICS
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
- (2012) Matthew J. Olnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
- (2011) K. Naqvi et al. BLOOD
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
- (2011) L. Malcovati et al. BLOOD
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
- (2011) I. A. Oussenko et al. CANCER RESEARCH
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
- (2011) L. Malcovati et al. HAEMATOLOGICA
- Targeting Immune Dysregulation in Myelodysplastic Syndromes
- (2011) Matthew J. Olnes JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
- (2011) Kiran Naqvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts
- (2011) E. Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA
- (2010) Hui Yang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
- (2010) M. G. Della Porta et al. HAEMATOLOGICA
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
- (2010) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
- (2010) Stuart L. Goldberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99
- (2010) Jakob R. Passweg et al. JOURNAL OF CLINICAL ONCOLOGY
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome
- (2009) R Garg et al. LEUKEMIA
- Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
- (2009) J X Zou et al. LEUKEMIA
- Myelodysplastic Syndromes
- (2009) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
- (2008) Victor Moyo et al. ANNALS OF HEMATOLOGY
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
- (2008) D. E. Rollison et al. BLOOD
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
- (2008) Hagop Kantarjian et al. CANCER
- Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
- (2008) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
- (2008) Mikkael A. Sekeres et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started